Table 4.
Risk factors for herpes zoster, univariable analysis.
| Variable (reference) | Cox proportional hazards Univariable analysis | |
|---|---|---|
| RR (95% CI) | p-value | |
| Gender (male) | 0.834 (0.559–1.245) | 0.374 |
| Age (continuous) | 1.012 (0.997–1.028) | 0.125 |
| Age ≥50 years | 1.672 (1.120–2.495) | 0.012 |
| Age ≥60 years | 1.355 (0.889–2.066) | 0.158 |
| Organ transplant (Heart) | 0.003 | |
|
Lung
Liver Kidney |
1.035 (0.579–1.850) 0.300 (0.159–0.565) 0.482 (0.297–0.783) |
0.907 <0.001 0.003 |
| VZV IgG pre-transplant (negative) | 2.370 (0.585–9.611) | 0.227 |
| Valganciclovir CMV prophylaxis (no) | 0.629 (0.430–0.922) | 0.017 |
| CMV prophylaxis (no) | 0.041 | |
|
Valganciclovir 3 months
Valganciclovir >6 months |
0.603 (0.404–0.900) 0.669 (0.289–1.547) |
0.013 0.347 |
| CMV prophylaxis (no) | 0.086 | |
|
Valganciclovir 3 months
Valganciclovir 6 months Valganciclovir 9 months |
0.603 (0.405–0.900) 0.752 (0.302–1.872) 0.430 (0.059–3.115) |
0.013 0.540 0.403 |
| Valganciclovir prophylaxis CMV R+ (no) a | 0.550 (0.337–0.898) | 0.017 |
| CMV-PCR >1,000 IU/ml | 1.012 (0.627–1.634) | 0.960 |
| Induction therapy (no) | 1.676 (1.114–2.522) | 0.013 |
| Induction therapy (no) | 0.035 | |
|
Basiliximab or Rituximab
rATG |
1.537 (0.952–2.482) 1.818 (1.144–2.887) |
0.078 0.011 |
| Induction therapy (no) | 0.059 | |
|
Basiliximab
rATG Rituximab |
1.484 (0.909–2.423) 1.817 (1.144–2.886) 2.432 (0.746–7.928) |
0.114 0.011 0.140 |
|
Anti-rejection therapy (no)
Methylprednisolone r-ATG |
0.531 (0.311–0.906) 1.301 (0.629–2.691) |
0.042 0.020 0.477 |
| r-ATG anti-rejection therapy (no) | 1.481 (0.720–3.050) | 0.286 |
VZV IgG, varicella zoster virus specific immunoglobulin G; CMV, cytomegalovirus; r-ATG, rabbit anti-thymocyte globulin; CMV R+, CMV seropositive recipient.
a
CMV seropositive recipients without Valganciclovir prophylaxis were compared to CMV seropositive recipients with Valganciclovir prophylaxis.